Spur Therapeutics’ Post

CAR-T is a gamechanger for cancer patients. But how does it compare to existing treatment? Let's break it down. Got some additional insight to add to this graphic? Drop it in the comments. For curated list of posts that simplify the science of cell and gene therapy, check out #cgt_simplified #biotechnology #cancertreatment #celltherapy

Advances in gene therapy are promising, but challenges like transient and off-target effects persist. Our latest blog explores key elements for safe, effective treatments: therapeutic genes, viral vectors, and promoters. Discover why promoters are crucial for improving therapy safety and efficacy. #genetherapy #viralvectors #drugdevelopment #ATMP #ASGCT https://lnkd.in/ep8ygrhM

In vivo CART therapy with modified LVs. Comparing with ex vivo CART, reducing COGs, no bridges therapy, expected low toxicity. Expecting clinical responses in patients without lymphodepletion or low-dose of lymphodepletion in a year.

Complement drug discovery is booming, and Svar is at the forefront with functional cell-based and immunoassay, and biomarker assays. Join us for the ultimate hub of scientific advancements, where we'll talk about the role of complement in AAV gene therapy, along with new poster for our cell-based anaphylatoxin assessment. Don't forget to connect with our scientific experts to discover customizable Complement System solutions for your project! If you're too busy during the event, you can always contact us here: https://hubs.ly/Q02BRTmB0 #ComplementSystem #ComplementBiology #DrugDevelopment #ComplementingLifeScience #AnswesInLifeScience

Tomorrow I will be presenting a poster covering the optimization of LNPs capable of delivering Poseida's Cas-CLOVER nuclease system to the liver using a novel class of ionizable lipids. Stop by poster 1737 to learn more! #ASGCT2024

For cell and gene therapies, characterizing products is an important step. But it’s also critical to determine that the product works - its functional activity/potency. Using our QC assays (flow cytometry, cell-based potency, automated imaging and analysis tools), we can determine your product’s: 🦠Delivery of transgene to cell 🧬Transgene expression 💉Successful translation into functional product This is essential at multiple stages of the product life cycle, including future clinical trials. Schedule a call with us to discover our capabilities in #CGT assays: https://lnkd.in/gas4KqvM #celltherapy #genetherapy #bioassays #bioanalyticallab #bioanalysis

Join Daniel Forsström, R&D Application and Custom Service Manager, on December 13th for a webinar that will revolutionize your plate-based ELISA assays and take your gene therapy development to the next level. 🚀 You will learn how automating your manual ELISA can save valuable time and resources and boost productivity. Case studies will illustrate how manual ELISA assays for viral titer and impurity analysis can be seamlessly transferred to the automated Gyrolab platform. Save the Date: 🗓️ December 13, 2023 ⏰ Wednesday 08:00 PST / 11:00 EST / 16:00 GMT / 17:00 CET 📍https://lnkd.in/dQR299kx Let's unlock the full potential of your research together! 💪 #GeneTherapy #ELISAAssays #GyrolabTechnnology #AutomatedImmunoassays #Webinar #Research #Productivity #Innovation #UnlockPotential

Patrick Paez, Ph.D. , Technical Marketing Manager, presented “A Next-Generation Plasmid Demonstrates to Improve Non-Viral Vector Manufacturing—Nanoplasmid” today at Biotech Week Boston. Nanoplasmid is a curated, next-gen plasmid vector that improves upon traditional pUC plasmids used in the cell and gene therapy field, providing several advantages -- which you can learn about here https://lnkd.in/g46atEd3

Always happy to see information presented on the Nanoplasmid. The Nanoplasmid brings many advantages that truly transform your development needs. #cellandgenetherapy #plasmid #nanoplasmid #vector #alwaysNTCgreen #Naturetechnology